
Zymeworks will receive $55 million upfront and may earn milestone payments and royalties as Roche takes global development rights to ZW209.
Zymeworks has signed a global license and collaboration agreement with Roche for its cancer drug candidate ZW209, with $55 million due upfront and up to $718 million in additional milestone payments.
Zymeworks may also receive $40 million when a Phase 1b trial begins and tiered royalties on future net sales of any approved medicines. The agreement remains subject to the expiration or termination of a U.S. antitrust waiting period and other closing conditions.
Zymeworks will conduct the Phase 1a monotherapy trial with Roche funding it. Roche will handle subsequent global development and commercialization, pending the deal’s completion.
As of 15:52 UTC on Friday, Zymeworks shares traded at $28.04, down 1.41% from the previous close.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.